Regal Assets Analytics

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

SanaCurrents on Prometheus’ (RXDX) precision medicine approach in ulcerative colitis & Crohn’s disease

By |2022-06-13T19:47:36-04:00June 12th, 2022|Tags: |

Prometheus Biosciences, Inc. (NASDAQ:RXDX) Probability Sentiment SUMMARY Early-stage investors continue to back new drugs for [...]

SanaCurrents on Rani’s (RANI) transformative RaniPill to deliver large molecule biologics

By |2022-06-06T00:47:00-04:00June 6th, 2022|Tags: |

$RANI Probability Sentiment Needles. Who enjoys needles? No one. If someone claims indifference to regular [...]

SanaCurrents Portfolio Update: APLS files NDA, IMUX UC drug falters in phase II topline, plus VERA and ACET

By |2022-06-13T19:48:07-04:00June 5th, 2022|Tags: , , , |

Apellis Pharmaceuticals (NASDAQ:APLS) on June 1 submitted an NDA for its drug pegcetacoplan to be approved to treat geographic atrophy [...]

SanaCurrents on FDA decision for uniQure’s (QURE) gene therapy to treat hemophilia B

By |2022-05-31T07:33:34-04:00May 31st, 2022|Tags: |

uniqure N.v. (NASDAQ:QURE) Probability Sentiment SUMMARY The inherited bleeding disorder hemophilia remains a lucrative rare [...]

SanaCurrents on PDFUA decision for Travere’s (TVTX) Sparsentan to treat IgAN

By |2022-05-31T07:32:25-04:00May 22nd, 2022|Tags: |

Travere Therapeutics, Inc. (NASDAQ:TVTX) Probability Sentiment SUMMARY Travere Therapeutics’ (NASDAQ:TVTX) received a PDUFA decision date [...]

SanaCurrents Speculative on Adicet’s (ACET) upcoming gamma-delta cancer data at the June ASCO meeting

By |2022-05-18T13:37:22-04:00May 14th, 2022|Tags: |

Adicet Bio, Inc. (NASDAQ:ACET) Probability Sentiment SUMMARY While first-generation, autologous chimeric antigen receptor (CAR) T [...]

SanaCurrents on Insmed’s (INSM) entry in pulmonary arterial hypertension (PAH)

By |2022-05-18T13:37:33-04:00May 7th, 2022|Tags: |

Insmed, Inc. (NASDAQ:INSM) Probability Sentiment SUMMARY Pulmonary arterial hypertension (PAH) comprises a group of severe [...]

Go to Top